Tim McCarthy, CEO of ImmuPharma PLC (AIM:IMM), has called the latest findings on the company’s key drug P140 "stunning results" that significantly enhance its commercial prospects.
The breakthrough study provides direct evidence of P140’s unique mechanism of action, confirming that it is both effective and, crucially, non-immunosuppressive.
Unlike many existing autoimmune treatments that weaken the immune system, P140 does not block the body’s ability to mount a specific immune response.
The results come from a new preclinical study carried out in a leading US laboratory. While full data will be released later, ImmuPharma says the findings will strengthen its intellectual property portfolio, opening the door to additional patents and increasing the drug’s commercial viability.
With the autoimmune therapy market expected to hit $360 billion in global sales by 2030, the company is well-positioned to attract licensing deals.
McCarthy said the findings would play a crucial role in ongoing discussions with potential partners as ImmuPharma looks to strike the best deal for shareholders.
Sébastien Goudreau, CEO of ImmuPharma Biotech, added: "These results are extremely compelling. Not only do they validate our MOA, they also indicate that P140 has the possibility to become a central treatment for a number of autoimmune diseases. Patients can be very hopeful, I certainly am."